UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 20, 2026 (November 17, 2026)

HCW Biologics Inc.
(Exact name of Registrant as Specified in Its Charter)

Delaware	**001-40591**	**82-5024477**
(State or Other Jurisdiction of Incorporation)	**(Commission File Number)**	**(IRS Employer Identification No.)**

2929 N. Commerce Parkway Miramar, Florida	**33025**
(Address of Principal Executive Offices)	**(Zip Code)**

Registrant's Telephone Number, Including Area Code: (954) 842-2024

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, par value $0.0001 per share	HCWB	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.07 Submission of Matters to a Vote of Security Holders.

On November 17, 2026, HCW Biologics Inc. ("HCW Biologics" or the "Company") convened a Special Meeting of Stockholders (the "November 2026 Special Meeting"). At that time, there were not present in person or represented by proxy a sufficient number of shares of the Company's common stock to constitute a quorum. Accordingly, the November 2026 Special Meeting was adjourned without any business being conducted, and no vote was taken on the proposal submitted to stockholders at the November 2026 Special Meeting to approve, for purposes of Nasdaq Listing Rule 5635(d), the issuance of shares of the Company's common stock upon exercise of common stock warrants exercisable for up to 618,682 shares of the Company's common stock at an exercise price of $2.585 per share, issued pursuant to the transaction documents entered into by the Company and certain investors in connection with the Company's private placement financing completed on July 29, 2026.

Item 8.01 Other Events.

The proposal submitted to stockholders for their approval at the November 2026 Special Meeting will be included in the proposals to be submitted to stockholders for their approval at a new Special Meeting of Stockholders, which will be held virtually at 10:00 A.M. Eastern Time on January 26, 2027 (the "January 2027 Special Meeting"). The record date for the January 2027 Special Meeting is December 15, 2026. Two proposals will be submitted to stockholders for their approval at the January 2027 Special Meeting: (i) the proposal from the November 2026 Special Meeting and (ii) a proposal to approve the issuance of shares of common stock upon exercise of the common stock warrants issued in the Company's private placement offering that closed on September 23, 2026, as required by Nasdaq Listing Rule 5635(d).

The Company filed a preliminary proxy statement on November 18, 2026 and, thereafter intends to file a definitive proxy statement on Schedule 14A (the "Proxy Statement") with the Securities and Exchange Commission (the "SEC") in connection with the January 2027 Special Meeting. The Company expects to file the definitive Proxy Statement on or about December 17, 2026. Stockholders are urged to read the Proxy Statement and other proxy materials relating to the January 2027 Special Meeting when they become available, because they will contain important information. Stockholders may obtain these documents, when available, free of charge on the SEC's website at *www.sec.gov*.

The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company's stockholders in connection with the January 2027 Special Meeting. Information regarding the names of such persons and their respective interests in the Company, by security holdings or otherwise, will be set forth in the Proxy Statement.

Prior to the January 2027 Special Meeting, the Company intends to solicit proxies from its stockholders with respect to the proposals to be set forth in the Proxy Statement.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HCW BIOLOGICS INC.

Date: November 20, 2026

By: */s/ Hing C. Wong*
Hing C. Wong, Founder and Chief Executive Officer